Net cash used in operating activities (USD, thousands)

Net cash (used in) provided by investing activities (USD, thousands)

Net cash provided by financing activities (USD, thousands)

Net Loss (USD, thousands)

(Accretion) amortization of investment premiums (USD, thousands)

Amortization of financing costs (USD, thousands)

Stock-based compensation (USD, thousands)

Amortization of right-of-use assets (USD, thousands)

Realized gain on investment (USD, thousands)

Interest expense related to operating lease liability (USD, thousands)

Purchases of investments (USD, thousands)

Proceeds from sales and maturities of investments (USD, thousands)

Public offering, net of offering costs (USD, thousands)

Value of shares withheld related to employee tax withholding (USD, thousands)

Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan (USD, thousands)

ATM offering, net of fees (USD, thousands)

Net (decrease) increase in cash and cash equivalents (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Accrued interest, net of interest receivable on maturity of investments (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses (USD, thousands)

Lease liability (USD, thousands)

05f3bada5ad85341b80039bd21cb1978cf9bea509fa9f7d9deccc52da878739f

Revenues (USD, thousands)

Research and Development Expenses (USD, thousands)

General and Administrative Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Amortization of Financing Costs (USD, thousands)

Interest Income, Net (USD, thousands)

Realized Loss on Investments, Net (USD, thousands)

Foreign Exchange Gain (USD, thousands)

Total Other Income, Net (USD, thousands)

Unrealized Gain (Loss) on Securities (USD, thousands)

Foreign Currency Translation Loss (USD, thousands)

Comprehensive Loss (USD, thousands)

Basic and Diluted Net Loss per Share (USD)

Weighted-Average Shares Used to Compute Basic and Diluted Net Loss Per Share (thousands)

82df2feacdb1d0fd1d0f5567b36857ebe6400c0b0899965f8e3a015a396f0c6a

Cash and cash equivalents (USD, thousands)

Short-term investments – available-for-sale (USD, thousands)

Prepaid clinical trial and preclinical study costs (USD, thousands)

Total current assets (USD, thousands)

Right-of-use assets (USD, thousands)

Deferred financing costs (USD, thousands)

Deposits (USD, thousands)

Total assets (USD, thousands)

Other accrued liabilities (USD, thousands)

Lease liability, current (USD, thousands)

Total current liabilities (USD, thousands)

Lease liability, net of current portion (USD, thousands)

Total long-term liabilities (USD, thousands)

Total liabilities (USD, thousands)

Preferred stock (USD, thousands)

Common stock (USD, thousands)

Treasury stock at cost (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive loss (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

904540bc0aafa710d35db08b0a0316a110e6a84efc5428d67910ed2fbd51f7ee

Maximum percent reduction in mean body weight from baseline for patients receiving weekly doses of VK2735, subcutaneous form (percentage)

Maximum percent reduction in mean body weight from baseline relative to placebo for patients receiving weekly doses of VK2735, subcutaneous form (percentage)

Maximum percent reduction in mean body weight from baseline for patients receiving VK2735, oral form (percentage)

Percent of patients treated with VK2809 achieving NASH resolution with no worsening of fibrosis (percentage)

Percent of patients receiving placebo achieving NASH resolution with no worsening of fibrosis (percentage)

Percent of patients treated with VK2809 achieving >=1-stage improvement in fibrosis with no worsening of NASH (percentage)

Percent of patients receiving placebo achieving >=1-stage improvement in fibrosis with no worsening of NASH (percentage)

Percent of patients receiving placebo achieving both resolution of NASH and a >=1-stage improvement in fibrosis (percentage)

f9fd1bcbf12eb83855745118eb05b6089a34d1918f3b7f03a562052302a365ab

Viking Therapeutics Inc (VKTX)

Financials